Company News – Updates & Industry Insights

Jun.01, 2025

CelluPro Leads Development of New Group Standard for Serum-Free Mammalian Cell Culture Medium

The group standard for Serum-Free Mammalian Cell Culture Medium (Standard No.: T/CSBME 086-2025), drafted under the leadership of Yantai CelluPro Biological Technology Co., Ltd., was officially released.

Mar.09, 2021

CelluPro’s Culture Media Contributes to the Successful Approval of the New Drug Telitacicept, a Class 1 Innovative Biological Product

On March 9, 2021, the National Medical Products Administration of China approved Telitacicept, a Class 1 innovative drug developed by RemeGen, for the treatment of systemic lupus erythematosus.

Jun.09, 2021

CelluPro Culture Media Supports China’s First Developed ADC New Drug Approval

On June 9, 2021, China's National Medical Products Administration (NMPA) announced the approval of Disitamab Vedotin (Brand Name: Aidixi®, Research Code: RC48), the country’s first original antibody-drug conjugate (ADC) new drug.